9 results about "Hepatitis A viruses" patented technology

The invention discloses a primer combination and a kit for detecting hepatitis A virus and application of the primer combination and the kit. The primer combination comprises at least one of the following combinations: (a) a forward primer SEQ ID NO: 3 and a reverse primer SEQ ID NO: 4; (b) a forward primer SEQ ID NO: 5 and a reverse primer SEQ ID NO: 6. According to the primer combination, through targeted region optimization, sequence design improvement and amplification parameter matching, the core pain point of an existing HAV detection technology is solved, and the primer combination has higher application value in quality detection of clinical diagnosis and cell therapy products.

The disclosure provides binding agents (e.g., antibodies) against a human Hepatitis A virus cellular receptor 2 protein (TIM3), as well as kits and methods for using the same (e.g., immunoassays) as part of a companion diagnostic and for other applications. In some aspects, the binding agents described herein may be used in assays for detecting Non-Small Cell Lung Cancer (NSCLC) and / or other types of lung cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Hepatocellular Carcinoma (HCC) or other types of liver cancer, Renal cell carcinoma, malignant melanoma, gastro-intestinal cancer, colorectal cancer, urothelial carcinoma and other types of bladder cancer, mamma carcinoma and / or other types of breast cancer, ovarian cancer, cervical cancer, prostate cancer, pancreatic cancer, lymphoma / leukemia, malignant mesothelioma, or a cancer in another organ or cell type.

The application discloses a method for constructing an animal model infected with hepatitis A virus and application thereof. Specifically disclosed is a method for constructing an animal model infected with hepatitis A virus, which comprises the following steps: encapsulating a complete genome RNA of hepatitis A virus in LNP to obtain LNP-encapsulated hepatitis A virus genome RNA; inoculating the LNP-encapsulated hepatitis A virus genome RNA into a non-human mammal to obtain the animal model infected with the hepatitis A virus. The LNP-encapsulated HAV genome RNA is obtained through gene synthesis, and is used as inoculating material of the animal infection model, so that the LNP-encapsulated HAV genome RNA is convenient to obtain and has good uniformity and repeatability. The application first establishes an animal model infected with hepatitis A virus without isolation and culture of the virus, and the virus can be directly established and amplified, and compared with a strain, the virus genome RNA is easier to obtain and safer to operate.

The present application relates to compositions and methods for detecting human parvovirus nucleic acid and for detecting hepatitis A virus nucleic acid in single or multiplex assays. In particular, the present application discloses nucleic acid oligomers specific for human parvovirus genomic DNA. Also disclosed is an assay for amplifying and detecting nucleic acid of human parvovirus genotypes 1, 2 and 3 in a biological specimen. Also disclosed are compositions for amplifying and detecting the presence of genomic DNA of human parvovirus genotypes 1, 2 and 3 in a human biological specimen.

The invention relates to the technical field of biological detection, and discloses an oligonucleotide composition, a kit and application. The composition disclosed by the invention can be used for rapidly and simultaneously detecting salmonella, shigella, entamoeba histolytica, vibrio cholerae, hepatitis A virus and hepatitis E virus in a sample with high specificity, and has relatively high sensitivity and stability. Compared with the traditional detection methods such as pathogen separation, genome sequencing and the like, the efficiency of identifying and detecting salmonella, shigella, entamoeba histolytica, vibrio cholerae, hepatitis A virus and hepatitis E virus by adopting the composition disclosed by the invention is effectively improved, the detection process is simple and convenient to operate, and the composition is suitable for large-scale popularization and application.

The invention relates to the technical field of hepatitis A virus detection, and provides an application of a hepatitis A virus detection technology based on an ultra-fast reverse transcription-free exponential amplification reaction (RTF-EXPAR), which comprises a primer composition, a fragment containing HAVRNA, a conjugate DNA (BinderDNA), a trigger X (TriggerX) and a template DNA (Template X '-X'), the reagent combination is divided into a part A, a part B and a part C, the total system is 33 microliters, and the detection process is as follows: the reagents are mixed according to the sequence of the part B, the part C and the part A, and the result is interpreted through a triple nucleic acid test strip (LFD) after isothermal amplification. Through the reverse transcription-free step, the total consumed time is shortened; according to the method, expensive instruments are not needed, a base layer is adapted, the HAVRNA detection limit is as low as 1.2 * 10 <-2 > nmol, early-stage trace viruses can be detected, cross reaction is avoided, and the method is adapted to multi-scene detection.

The application belongs to the technical field of medicine, and particularly relates to application of a jingfang preparation in prevention or treatment of type A viral hepatitis. Pharmacological experiments show that the jingfang preparation has a significant inhibitory effect on serum HAV-DNA level of infected ducks, can significantly inhibit the activity of type A hepatitis virus, and can be used for prevention and treatment of type A viral hepatitis, has a definite clinical curative effect, and is superior to jingfang baidu powder with modifications, and has a broad clinical application prospect.

This invention provides a capture probe set for whole-genome sequencing of hepatitis A virus (HAV). The nucleotide sequences of the capture probe set are shown in SEQ ID No:1 to SEQ ID No:880. This capture probe set can be used to prepare kits for whole-genome sequencing of HAV. This invention also provides a method for whole-genome sequencing of HAV using the capture probe set. The method involves liquid-phase hybridization of a total RNA library from a sample to be tested with the capture probe set. DNA fragments hybridized with the capture probe set are isolated from the hybridization reaction solution. These DNA fragments are then used as templates for capture-and-PCR amplification. The PCR products are sequenced, and after data analysis, the full-length HAV genome sequence is obtained. The capture probe set designed in this invention can capture the HAV genome. By optimizing the probe length, it can specifically enrich ultra-low copy numbers of the viral genome from high-background host nucleic acids, showing broad application prospects.

The invention discloses a hepatitis A vaccine virus titer trace detection method, a kit and application. Comprising the following steps: inoculating human diploid cells into a porous cell culture plate, and culturing to form monolayer cells; inoculating a to-be-detected hepatitis A virus sample into the porous cell culture plate with monolayer cells, carrying out virus adsorption and culture, marking as an experimental group, and taking human diploid cells not inoculated with the virus sample as a negative control group; adding acetone into the experimental group and the negative control group for incubation so as to lyse cells and fix hepatitis A viruses and antigens thereof; detecting by adopting an enzyme-linked immunosorbent assay, and calculating according to a detection result to obtain the virus titer of the hepatitis A virus sample to be detected. The method is simple and convenient to operate, a virus extraction step in a traditional method is omitted, reagents are remarkably saved, the detection flux is improved, and the method is highly related to results of a pharmacopoeia method and is suitable for vaccine process research and development and quality control.